PCM
NWBO

Prelude Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Prelude Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-700
Closed – – 2067
2016
Q2 		$0 Buy
+700
New +$747 ﹤0.01% 1922

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's NWBO Position: Q3 2016 in Review

Prelude Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 700 shares.

Prelude Capital Management first reported a position in NWBO in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

  • Prelude Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
  • Prelude Capital Management sold 700 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016.
  • Prelude Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2016 and held it in 1 quarter.
  • Prelude Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q2 2016.
  • 54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Prelude Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.